Truist Financial Corp Purchases 14,770 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Truist Financial Corp grew its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 38.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 52,887 shares of the financial services provider’s stock after buying an additional 14,770 shares during the quarter. Truist Financial Corp’s holdings in iShares Biotechnology ETF were worth $6,992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC increased its position in iShares Biotechnology ETF by 2.5% during the 4th quarter. Chicago Partners Investment Group LLC now owns 3,783 shares of the financial services provider’s stock worth $510,000 after buying an additional 94 shares during the period. Capital Investment Advisors LLC grew its holdings in shares of iShares Biotechnology ETF by 1.0% during the 4th quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock worth $1,381,000 after purchasing an additional 99 shares in the last quarter. Magnus Financial Group LLC grew its holdings in shares of iShares Biotechnology ETF by 0.8% during the 4th quarter. Magnus Financial Group LLC now owns 12,967 shares of the financial services provider’s stock worth $1,714,000 after purchasing an additional 104 shares in the last quarter. Burke & Herbert Bank & Trust Co. grew its holdings in shares of iShares Biotechnology ETF by 1.2% during the 4th quarter. Burke & Herbert Bank & Trust Co. now owns 8,809 shares of the financial services provider’s stock worth $1,165,000 after purchasing an additional 105 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in shares of iShares Biotechnology ETF by 12.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 1,028 shares of the financial services provider’s stock worth $150,000 after purchasing an additional 110 shares in the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

IBB opened at $138.91 on Friday. iShares Biotechnology ETF has a 52-week low of $123.60 and a 52-week high of $150.57. The business’s fifty day moving average is $135.61 and its 200-day moving average is $140.77.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were issued a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.